Dual EGFR/IGFR1 inhibitors (Ranbaxy Laboratories)

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameDual EGFR/IGFR1 inhibitors (Ranbaxy Laboratories)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin-like growth factor I receptor inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsInsulin-like growth factor I receptorEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRanbaxy Laboratories Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRanbaxy Laboratories Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A